Inclusion Criteria
Concurrent Medication:
Allowed:
- Patients who require anti-diarrheal medication must have received only one anti-diarrheal medication, loperamide, for at least 7 days prior to study entry. Dose of loperamide cannot be increased during study.
- Aerosolized pentamidine.
- Ganciclovir for cytomegalovirus (CMV) retinitis only but patient must be stable at least 4 weeks prior to study entry.
- Zidovudine (AZT).
- Nystatin for oropharyngeal infections if not taken within 2 hours of diclazuril.
Patients must have:
- Diagnosis of AIDS that is confirmed HIV positive by Western blot or AIDS defined diagnosis, or CDC defined AIDS. Stool specimens positive for cryptosporidium oocysts.
- Given written informed consent after the purpose and nature of the study, as well the possible drug-related adverse effects, have been explained.
- Ability to return for all subsequent applicable visits on days 8, 15, 21, and, if necessary, 28.
Prior Medication:
Allowed:
- Aerosolized pentamidine.
- Loperamide.
- Ganciclovir for cytomegalovirus (CMV) retinitis.
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
- Diagnosis of cryptosporidiosis less than 4 weeks prior to study entry, unless patient has been diagnosed with AIDS for more than 4 weeks.
- Other treatable enteric pathogens including Clostridia must be treated and eradicated prior to study entry.
- Inability to swallow capsules.
- Uncontrolled vomiting.
Concurrent Medication:
Excluded:
- Trimethoprim/sulfamethoxazole (Bactrim).
- Ganciclovir for any other reason except cytomegalovirus (CMV) retinitis.
- Other antibiotics.
- Other anti-protozoal drugs.
- Anti-fungal drugs other than nystatin.
- Amphotericin B.
- Other investigational drugs.
Patients with the following are excluded:
- Diagnosis of cryptosporidiosis less than 4 weeks prior to study entry, unless patient has been diagnosed with AIDS for more than 4 weeks.
- Inability to swallow capsules.
- Uncontrolled vomiting.
- Life expectancy of < 28 days.
- Can not be depended upon to follow the instructions of the investigator.
- Participation in an investigational study within 15 days of study entry.
Prior Medication:
Excluded within 15 days of study entry:
- Another investigational drug or device (except aerosolized pentamidine).
Prior Treatment:
Excluded within 15 days of study entry:
- Participation in an investigational study.
Purpose
